First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018

Szu-Min Hsieh, Wang-Da Liu, Yu-Shan Huang, Yi-Jiun Lin, Erh-Fang Hsieh, Wei-Cheng Lian, Charles Chen, I-Chen Tai, Shan-Chwen Chang
doi: https://doi.org/10.1101/2021.03.31.21254668

Article usage

Article usage: April 2021 to December 2024

AbstractFullPdf
Apr 20216287439872
May 202132801736609
Jun 20211474817754972
Jul 20211325386283
Aug 202111531241523
Sep 2021602411969
Oct 20212741884
Nov 20211551746
Dec 20211362540
Jan 20221201241
Feb 202284521
Mar 202254317
Apr 202281327
May 202268318
Jun 20226511107
Jul 2022442108
Aug 202236313
Sep 202253321
Oct 202247620
Nov 202240112
Dec 202224319
Jan 202333113
Feb 202333416
Mar 20232004
Apr 202337510
May 20232398
Jun 20239514
Jul 20231129
Aug 2023251011
Sep 202317412
Oct 20232423
Nov 2023421415
Dec 20231704
Jan 202418211
Feb 202419411
Mar 202423415
Apr 202431611
May 202419317
Jun 202419411
Jul 202417518
Aug 202420612
Sep 202427512
Oct 20241637
Nov 202421115
Dec 20241117
Back to top
Posted April 06, 2021.
Download PDF
Data/Code
Email
First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018
Szu-Min Hsieh, Wang-Da Liu, Yu-Shan Huang, Yi-Jiun Lin, Erh-Fang Hsieh, Wei-Cheng Lian, Charles Chen, I-Chen Tai, Shan-Chwen Chang
medRxiv 2021.03.31.21254668; doi: https://doi.org/10.1101/2021.03.31.21254668
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area